Correlation Between EPIRUS Biopharmaceutica and Novo Nordisk

Can any of the company-specific risk be diversified away by investing in both EPIRUS Biopharmaceutica and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining EPIRUS Biopharmaceutica and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between EPIRUS Biopharmaceuticals and Novo Nordisk AS, you can compare the effects of market volatilities on EPIRUS Biopharmaceutica and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in EPIRUS Biopharmaceutica with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of EPIRUS Biopharmaceutica and Novo Nordisk.

Diversification Opportunities for EPIRUS Biopharmaceutica and Novo Nordisk

0.0

Correlation Coefficient

EPIRUS Biopharmaceutica  Novo Nordisk

Pay attention - limited upside

The 3 months correlation between EPIRUS and Novo is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding EPIRUS Biopharmaceuticals and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and EPIRUS Biopharmaceutica is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on EPIRUS Biopharmaceuticals are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of EPIRUS Biopharmaceutica i.e., EPIRUS Biopharmaceutica and Novo Nordisk go up and down completely randomly.

Pair Corralation between EPIRUS Biopharmaceutica and Novo Nordisk

If you would invest  0.01  in EPIRUS Biopharmaceuticals on September 13, 2024 and sell it today you would earn a total of  0.00  from holding EPIRUS Biopharmaceuticals or generate 0.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	1.56%
Values	Daily Returns

EPIRUS Biopharmaceuticals  vs.  Novo Nordisk AS

EPIRUS Biopharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days EPIRUS Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, EPIRUS Biopharmaceutica is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Novo Nordisk AS

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with EPIRUS Biopharmaceutica and Novo Nordisk

The main advantage of trading using opposite EPIRUS Biopharmaceutica and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if EPIRUS Biopharmaceutica position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.

The idea behind EPIRUS Biopharmaceuticals and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.